Form 4: Revolution Medicines Executive Sells Shares to Cover Tax Obligations

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,665 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,665 shares of common stock on September 16, 2024.
• The sale was executed at a price of $44.1853 per share.
• The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023.
• The purpose of the sale was to satisfy the reporting person's tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following the transaction, Kelsey still beneficially owns 264,408 shares of Revolution Medicines, Inc., including 86,400 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral event. An executive selling shares to cover tax obligations is a common occurrence and doesn't necessarily reflect a positive or negative outlook on the company.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This is a routine Form 4 filing, reflecting an executive's stock sale to cover tax obligations. Such transactions are common and generally don't indicate a change in the company's prospects.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates